James J McAleer

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 76 citations · Full text

Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer

Bruno Reigner, Toru Watanabe, Johannes Sch�ller et al. · Cancer Chemotherapy and Pharmacology · 2003 · 46 citations

Breast Oncology, Oncology, Pharmacology +5

Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence

Miranda Payne, Katerina Argyropoulou, Paul Lorigan et al. · Journal of Clinical Oncology · 2013 · 44 citations · Full text

Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours?

James J McAleer, J. Nicholls, A. Horwich · European Journal of Cancer · 1992 · 18 citations

Surgical Oncology, Tumoral Pathology, Gastrointestinal Oncology +9

Broadcast Quality Teleconferencing for Oncology

James J McAleer, Desmond O'Loan, Donal Hollywood · The Oncologist · 2001 · 16 citations · Full text

National Cancer Institute, Telemetry, Wireless Telemedicine +15